Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patientsTeresa Amaral, Lisa Zimmer, Lydia Reinhardt et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 88
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trialJürgen C. Becker, Lucie Heinzerling, Selma Ugurel et al.|The Lancet|2023Cited by 75
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg StudyHenner Stege, Carmen Loquai, Maximilian Haist et al.|Cancers|2021Cited by 23
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Carmen Loquai, Henner Stege et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 18
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREGSören Reinhard, Henner Stege, Jochen Utikal et al.|European Journal of Cancer|2025Cited by 4